α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: Relevance to human synucleopathic diseases

Zane S. Martin, Volker Neugebauer, Kelly Dineley, Rakez Kayed, Wenru Zhang, Lindsay C. Reese, Giulio Taglialatela

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Intracellular deposition of fibrillar aggregates of α-synuclein (αSyn) characterizes neurodegenerative diseases such as Parkinson's disease (PD) and dementia with Lewy bodies. However, recent evidence indicates that small αSyn oligomeric aggregates that precede fibril formation may be the most neurotoxic species and can be found extracellularly. This new evidence has changed the view of pathological αSyn aggregation from a self-contained cellular phenomenon to an extracellular event and prompted investigation of the putative effects of extracellular αSyn oligomers. In this study, we report that extracellular application of αSyn oligomers detrimentally impacts neuronal welfare and memory function. We found that oligomeric αSyn increased intracellular Ca 2+ levels, induced calcineurin (CaN) activity, decreased cAMP response element-binding protein (CREB) transcriptional activity and resulted in calcineurin-dependent death of human neuroblastoma cells. Similarly, CaN induction and CREB inhibition were observed when αSyn oligomers were applied to organotypic brain slices, which opposed hippocampal long-term potentiation. Furthermore, αSyn oligomers induced CaN, inhibited CREB and evoked memory impairments in mice that received acute intracerebroventricular injections. Notably, all these events were reversed by pharmacological inhibition of CaN. Moreover, we found decreased active CaN and reduced levels of phosphorylated CREB in autopsy brain tissue from patients affected by dementia with Lewy bodies, which is characterized by deposition of αSyn aggregates and progressive cognitive decline. These results indicate that exogenously applied αSyn oligomers impact neuronal function and produce memory deficits through mechanisms that involve CaN activation. Reversing the cognitive effects of the ParkinsonÂ's disease protein alpha synucleinThe present study was performed to investigate neuronal and behavioral effects elicited by small aggregates (oligomers) of α-synuclein, the toxic protein present in the brain of patients affected by severe neurological disorders such as Parkinson's disease and dementia with Lewy bodies. We found that extracellularly delivered α-synuclein oligomers profoundly affect neuronal function and induce acute memory deficits that occurred independently of neuronal death and that could be reversed by inhibiting a specific neuronal enzyme. Notably, evidence of such an effect could be also observed in actual diseased human brain specimens. These novel results illustrate that some cognitive impairments normally seen in human neurological diseases involving α-synuclein precede overt neuronal death and suggest an effective pharmacological target to treat them, possibly delaying further progression of the disease.

Original languageEnglish (US)
Pages (from-to)440-452
Number of pages13
JournalJournal of Neurochemistry
Volume120
Issue number3
DOIs
StatePublished - Feb 2012

Fingerprint

Synucleins
Long-Term Potentiation
Calcineurin
Oligomers
Data storage equipment
Cyclic AMP Response Element-Binding Protein
Lewy Body Disease
Brain
Parkinson Disease
Memory Disorders
Pharmacology
Neurodegenerative diseases
Poisons
Brain Diseases
Nervous System Diseases

Keywords

  • α-synuclein
  • calcineurin
  • DLB
  • LTP
  • memory
  • oligomers

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism : Relevance to human synucleopathic diseases. / Martin, Zane S.; Neugebauer, Volker; Dineley, Kelly; Kayed, Rakez; Zhang, Wenru; Reese, Lindsay C.; Taglialatela, Giulio.

In: Journal of Neurochemistry, Vol. 120, No. 3, 02.2012, p. 440-452.

Research output: Contribution to journalArticle

@article{893498f47cec428f9fb05448e3dd8ce1,
title = "α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: Relevance to human synucleopathic diseases",
abstract = "Intracellular deposition of fibrillar aggregates of α-synuclein (αSyn) characterizes neurodegenerative diseases such as Parkinson's disease (PD) and dementia with Lewy bodies. However, recent evidence indicates that small αSyn oligomeric aggregates that precede fibril formation may be the most neurotoxic species and can be found extracellularly. This new evidence has changed the view of pathological αSyn aggregation from a self-contained cellular phenomenon to an extracellular event and prompted investigation of the putative effects of extracellular αSyn oligomers. In this study, we report that extracellular application of αSyn oligomers detrimentally impacts neuronal welfare and memory function. We found that oligomeric αSyn increased intracellular Ca 2+ levels, induced calcineurin (CaN) activity, decreased cAMP response element-binding protein (CREB) transcriptional activity and resulted in calcineurin-dependent death of human neuroblastoma cells. Similarly, CaN induction and CREB inhibition were observed when αSyn oligomers were applied to organotypic brain slices, which opposed hippocampal long-term potentiation. Furthermore, αSyn oligomers induced CaN, inhibited CREB and evoked memory impairments in mice that received acute intracerebroventricular injections. Notably, all these events were reversed by pharmacological inhibition of CaN. Moreover, we found decreased active CaN and reduced levels of phosphorylated CREB in autopsy brain tissue from patients affected by dementia with Lewy bodies, which is characterized by deposition of αSyn aggregates and progressive cognitive decline. These results indicate that exogenously applied αSyn oligomers impact neuronal function and produce memory deficits through mechanisms that involve CaN activation. Reversing the cognitive effects of the Parkinson{\^A}'s disease protein alpha synucleinThe present study was performed to investigate neuronal and behavioral effects elicited by small aggregates (oligomers) of α-synuclein, the toxic protein present in the brain of patients affected by severe neurological disorders such as Parkinson's disease and dementia with Lewy bodies. We found that extracellularly delivered α-synuclein oligomers profoundly affect neuronal function and induce acute memory deficits that occurred independently of neuronal death and that could be reversed by inhibiting a specific neuronal enzyme. Notably, evidence of such an effect could be also observed in actual diseased human brain specimens. These novel results illustrate that some cognitive impairments normally seen in human neurological diseases involving α-synuclein precede overt neuronal death and suggest an effective pharmacological target to treat them, possibly delaying further progression of the disease.",
keywords = "α-synuclein, calcineurin, DLB, LTP, memory, oligomers",
author = "Martin, {Zane S.} and Volker Neugebauer and Kelly Dineley and Rakez Kayed and Wenru Zhang and Reese, {Lindsay C.} and Giulio Taglialatela",
year = "2012",
month = "2",
doi = "10.1111/j.1471-4159.2011.07576.x",
language = "English (US)",
volume = "120",
pages = "440--452",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism

T2 - Relevance to human synucleopathic diseases

AU - Martin, Zane S.

AU - Neugebauer, Volker

AU - Dineley, Kelly

AU - Kayed, Rakez

AU - Zhang, Wenru

AU - Reese, Lindsay C.

AU - Taglialatela, Giulio

PY - 2012/2

Y1 - 2012/2

N2 - Intracellular deposition of fibrillar aggregates of α-synuclein (αSyn) characterizes neurodegenerative diseases such as Parkinson's disease (PD) and dementia with Lewy bodies. However, recent evidence indicates that small αSyn oligomeric aggregates that precede fibril formation may be the most neurotoxic species and can be found extracellularly. This new evidence has changed the view of pathological αSyn aggregation from a self-contained cellular phenomenon to an extracellular event and prompted investigation of the putative effects of extracellular αSyn oligomers. In this study, we report that extracellular application of αSyn oligomers detrimentally impacts neuronal welfare and memory function. We found that oligomeric αSyn increased intracellular Ca 2+ levels, induced calcineurin (CaN) activity, decreased cAMP response element-binding protein (CREB) transcriptional activity and resulted in calcineurin-dependent death of human neuroblastoma cells. Similarly, CaN induction and CREB inhibition were observed when αSyn oligomers were applied to organotypic brain slices, which opposed hippocampal long-term potentiation. Furthermore, αSyn oligomers induced CaN, inhibited CREB and evoked memory impairments in mice that received acute intracerebroventricular injections. Notably, all these events were reversed by pharmacological inhibition of CaN. Moreover, we found decreased active CaN and reduced levels of phosphorylated CREB in autopsy brain tissue from patients affected by dementia with Lewy bodies, which is characterized by deposition of αSyn aggregates and progressive cognitive decline. These results indicate that exogenously applied αSyn oligomers impact neuronal function and produce memory deficits through mechanisms that involve CaN activation. Reversing the cognitive effects of the ParkinsonÂ's disease protein alpha synucleinThe present study was performed to investigate neuronal and behavioral effects elicited by small aggregates (oligomers) of α-synuclein, the toxic protein present in the brain of patients affected by severe neurological disorders such as Parkinson's disease and dementia with Lewy bodies. We found that extracellularly delivered α-synuclein oligomers profoundly affect neuronal function and induce acute memory deficits that occurred independently of neuronal death and that could be reversed by inhibiting a specific neuronal enzyme. Notably, evidence of such an effect could be also observed in actual diseased human brain specimens. These novel results illustrate that some cognitive impairments normally seen in human neurological diseases involving α-synuclein precede overt neuronal death and suggest an effective pharmacological target to treat them, possibly delaying further progression of the disease.

AB - Intracellular deposition of fibrillar aggregates of α-synuclein (αSyn) characterizes neurodegenerative diseases such as Parkinson's disease (PD) and dementia with Lewy bodies. However, recent evidence indicates that small αSyn oligomeric aggregates that precede fibril formation may be the most neurotoxic species and can be found extracellularly. This new evidence has changed the view of pathological αSyn aggregation from a self-contained cellular phenomenon to an extracellular event and prompted investigation of the putative effects of extracellular αSyn oligomers. In this study, we report that extracellular application of αSyn oligomers detrimentally impacts neuronal welfare and memory function. We found that oligomeric αSyn increased intracellular Ca 2+ levels, induced calcineurin (CaN) activity, decreased cAMP response element-binding protein (CREB) transcriptional activity and resulted in calcineurin-dependent death of human neuroblastoma cells. Similarly, CaN induction and CREB inhibition were observed when αSyn oligomers were applied to organotypic brain slices, which opposed hippocampal long-term potentiation. Furthermore, αSyn oligomers induced CaN, inhibited CREB and evoked memory impairments in mice that received acute intracerebroventricular injections. Notably, all these events were reversed by pharmacological inhibition of CaN. Moreover, we found decreased active CaN and reduced levels of phosphorylated CREB in autopsy brain tissue from patients affected by dementia with Lewy bodies, which is characterized by deposition of αSyn aggregates and progressive cognitive decline. These results indicate that exogenously applied αSyn oligomers impact neuronal function and produce memory deficits through mechanisms that involve CaN activation. Reversing the cognitive effects of the ParkinsonÂ's disease protein alpha synucleinThe present study was performed to investigate neuronal and behavioral effects elicited by small aggregates (oligomers) of α-synuclein, the toxic protein present in the brain of patients affected by severe neurological disorders such as Parkinson's disease and dementia with Lewy bodies. We found that extracellularly delivered α-synuclein oligomers profoundly affect neuronal function and induce acute memory deficits that occurred independently of neuronal death and that could be reversed by inhibiting a specific neuronal enzyme. Notably, evidence of such an effect could be also observed in actual diseased human brain specimens. These novel results illustrate that some cognitive impairments normally seen in human neurological diseases involving α-synuclein precede overt neuronal death and suggest an effective pharmacological target to treat them, possibly delaying further progression of the disease.

KW - α-synuclein

KW - calcineurin

KW - DLB

KW - LTP

KW - memory

KW - oligomers

UR - http://www.scopus.com/inward/record.url?scp=84862908978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862908978&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2011.07576.x

DO - 10.1111/j.1471-4159.2011.07576.x

M3 - Article

C2 - 22060133

AN - SCOPUS:84862908978

VL - 120

SP - 440

EP - 452

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 3

ER -